Splenda® helps people reduce added sugars while keeping the sweetness and enjoyment they expect. A trusted brand, backed by evidence, built to support the conversations you have every day.
Patients asking about a recent sweetener headline? See how the weight of the evidence answers it in Common Questions.
A full low- and no-calorie sweetener portfolio: sucralose, stevia, monk fruit, and allulose, plus liquids, creamers, and other products.
See the benefits →Added sugars are concentrated in beverages and everyday foods. Splenda® gives patients a realistic way to cut added sugars while keeping the sweetness they enjoy.
Patient resources →Helps patients cut added sugars while keeping the sweetness and enjoyment they expect.
Preview the benefit →Across randomized trials, no significant effect on postprandial glucose or insulin response.
Preview the benefit →Replacing sugar energy intake with low- and no-calorie sweeteners is shown to reduce body weight.
Preview the benefit →A year-long randomized trial (the SWEET study) found beneficial shifts in gut microbiota.
Preview the benefit →Fits dietary approaches for patients on GLP-1 medications, consistent with advice to limit added sugar.
Preview the benefit →Stevia grown on a U.S. farm in Florida, with a farm-to-table story you can lean into with patients.
Learn more →The #1 sweetener brand recommended by healthcare professionals, a name your patients already recognize.
Learn more →Broadly available where your patients already shop, making the recommendation easy to act on.
Learn more →Recommend Splenda®, your patient scans a QR code to enroll, and Splenda® delivers product matches, digital coupons, and ongoing support.
No extra work for your practice.
Downloadable handouts, diabetes-friendly recipes, and patient testimonials to support the low-sugar conversation.
Browse resources →CE-oriented webinars and podcasts on sugar reduction, diabetes management, and sweetener science.
Continue learning →Swapping my afternoon soda for a sparkling water with Splenda® was the first change I actually stuck with.
My dietitian gave me the two-week plan. Cutting back on sugar felt manageable instead of all-or-nothing.
I didn’t think I could bake without sugar. The muffin recipe changed my mind, and my A1C conversation.
Illustrative testimonials for prototype purposes. Replace with reviewed, consented patient statements before deployment.
Explore the evidence on the health topics most relevant to your patients, from sugar reduction and blood glucose to weight management, safety, and emerging areas of research. For quick talking points, see Explore the Benefits; for patient objections, see Common Questions.
No significant effect on postprandial glucose or insulin across randomized trials. Allulose may modestly lower post-meal glucose.
Explore the evidence →Replacing sugar energy intake with low- and no-calorie sweeteners reduces body weight and BMI.
Explore the evidence →Why replacing added sugar matters, and how the comparison to sugar (not water) frames the benefit.
Explore the evidence →Decades of regulatory review, established ADIs, and how real-world intake compares. Includes regulatory status.
See the ADI tool →What the studies (Pang/SWEET, Suez 2022, and others) show, and how regulators weighed them.
Explore the evidence →The 2023 erythritol report was observational and about a distinct ingredient. It does not apply to sucralose, stevia, or monk fruit.
Explore the evidence →No study links Splenda® sweeteners to dementia. The concerns come from observational studies of diet beverages in general, not sucralose.
Explore the evidence →The domain-by-domain evidence summary across glycemic, microbiome, and safety endpoints.
Explore the evidence →The quick case for each benefit: what Splenda® offers and what it means for your patients. For the referenced detail, follow any benefit into Clinical Evidence. For patient objections, see Common Questions.
A way to keep beverages and foods sweet without the glucose load of added sugar, so patients can protect time in range.
Across randomized trials, no significant effect on postprandial glucose or insulin. The ADA supports non-nutritive sweeteners as a short-term substitute for sugar-sweetened products.
For patients managing blood glucose, substituting Splenda® for sugar is a defensible step that supports time-in-range goals.
A practical way to cut calories from added sugars while keeping the sweetness patients expect, which supports calorie-reduction goals.
Replacing sugar energy intake with low- and no-calorie sweeteners is shown to reduce body weight and BMI versus sugar. This is a class-level benefit stated against a sugar comparator.
For patients working toward a healthier BMI, Splenda® supports the calorie reduction that drives weight change.
Added sugars are concentrated in beverages and everyday foods. Splenda® makes it realistic for patients to cut them without losing enjoyment.
The harms of excess added sugar are well established. The relevant clinical choice is sugar or a substitute, and on that comparison the evidence favors substitution.
Replacing added sugar with Splenda® displaces calories that crowd out quality nutrition and hydration.
A single, low-friction change that patients can sustain across the day, supporting broader metabolic goals.
The domain-by-domain evidence, from glycemic response to the microbiome, supports sucralose as a viable option for sugar reduction.
The totality of evidence supports Splenda® as part of a lower-sugar dietary pattern.
An option patients can use daily while the science on the microbiome continues to develop.
A year-long randomized trial (the SWEET study) found beneficial shifts in gut microbiota. Regulators reviewed the fuller body of evidence and maintained their safety position.
For patients weighing sugar versus a Splenda® alternative, the harms of excess sugar remain the primary consideration.
When appetite is suppressed, patients still need hydration, protein, and fiber. Splenda® helps them enjoy a sweet beverage while sustaining these, supporting social and lifestyle needs.
A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society supports limiting added sugar during GLP-1 therapy.
Splenda® fits dietary approaches for patients on GLP-1 medications. Framed as consistent with advisory guidance to limit added sugar, not as an endorsement.
Stevia grown on a U.S. farm in Florida, with a farm-to-table story and a "how it is made" narrative you can lean into with patients who value it.
An option that connects a familiar brand to domestic sourcing patients can feel good about.
The #1 sweetener brand recommended by healthcare professionals, a recognized name HCPs and patients already know, which lowers the barrier to acting on a recommendation.
A recommendation carries weight when it comes with a brand patients recognize and can find easily.
Broad availability where your patients already shop, so a recommendation is easy to act on.
Fewer barriers between your recommendation and the patient making the swap.
Confident responses to the questions and misinformation HCPs hear most. Each answer links to the underlying Clinical Evidence.
Most questions come from misleading coverage of single studies. A few things help put that coverage in context:
The objection is usually about non-nutritive sweeteners as a category. The confident response is about Splenda®. Each answer includes what you can tell your patient, and links to the underlying evidence.
They are among the most studied ingredients in the food supply, and typical use is well within established safety limits. Decades of regulatory review have established safe conditions of use, and everyday intake is far below the acceptable daily intake.
“These are some of the most studied ingredients we have. The amount you would use day to day is far below the safety limits regulators set.”
At normal intakes, human evidence does not show that sucralose harms the gut microbiome. A year-long randomized trial found favorable shifts, and regulators reviewed the fuller body of evidence and reaffirmed safety.
“At the amounts people actually use, the human studies don’t show harm to your gut. One year-long study even found favorable changes.”
No regulatory authority classifies these sweeteners as carcinogens. The 2026 EFSA re-evaluation of sucralose found no genotoxicity concern and kept the acceptable daily intake unchanged.
“No health authority classifies these sweeteners as something that causes cancer.”
No. Sucralose, stevia, and monk fruit are glucose-neutral; allulose may lower the post-meal rise. Across randomized trials, sucralose has no significant effect on postprandial glucose or insulin.
“These sweeteners don’t raise your blood sugar the way sugar does.”
Yes. The ADA supports using non-nutritive sweeteners in place of sugar-sweetened products, in moderation and for the short term, to reduce calorie and carbohydrate intake.
“Yes. Diabetes guidelines support using them in place of sugar to cut calories and carbs, used in moderation.”
No. Replacing sugar with low- and no-calorie sweeteners is shown to reduce body weight, and the evidence does not show increased appetite that outweighs the calorie savings versus sugar.
“Swapping sugar for these can help with weight, not against it. Studies show weight loss when they replace sugar.”
No. The 2023 report that raised this was about erythritol, a distinct ingredient, and was observational. Its findings do not apply to sucralose, stevia, monk fruit, or allulose.
“That news was about a different ingredient, erythritol, not Splenda’s sweeteners, and it couldn’t show cause and effect.”
No study has linked Splenda® sweeteners to dementia. The concerns trace to observational studies of diet beverages in general, not sucralose, and the most publicized recent study did not measure the sweeteners in the Splenda® portfolio.
“No study has tied Splenda’s sweeteners to dementia. Those headlines looked at diet drinks in general and couldn’t show cause and effect.”
Patient handouts and recipes, professional education, and the Splenda® Sweet Swap program, all in one place.
How to spot added sugars on a Nutrition Facts label, and why they matter for blood glucose.
Download →Simple, realistic substitutions patients can make in coffee, baking, and snacks.
Download →A plain-language guide to carbohydrates, total sugars, and added sugars.
Download →What non-nutritive sweeteners are, how they differ, and what the evidence says, written for patients.
Download →A printable shopping checklist organized by aisle to make lower-sugar choices easier.
Download →A gentle 14-day starter plan patients can follow after your recommendation.
Download →View recipe →
View recipe →
View recipe →
View recipe →
Browse the full diabetes-friendly recipe collection on splenda.com.
Referenced summaries by topic, drawn from the full evidence base.
Go to Clinical Evidence →Recorded and upcoming sessions on the evidence, the 2026 EFSA re-evaluation, and counseling strategy.
View webinars →A "what I tell my patient" guide keyed to Common Questions. Content to be developed.
Download guide →Help patients match the right Splenda® product to their needs. Tool to be built.
Open product finder →Recommend once, and Splenda® Sweet Swap supports your patients with samples, savings, and sugar-reduction guidance. No forms to manage afterward.
Register your practice once to opt in. It takes a minute and there is nothing to manage afterward.
You receive patient-facing QR cards and samples to hand out during a low-sugar conversation.
Patients scan their card to enroll and receive product matches, savings, and ongoing guidance.
Opt in on the Splenda® Professionals site to get free samples and patient-facing Sweet Swap materials for your office. No forms to manage afterward.
Sign up for free resources →Healthcare professional sign-up · splenda.com/professionals
After you sign up, we provide pre-printed patient QR cards and samples to hand out in your office. Patients scan their card to enroll, so the enrollment link is not posted publicly.
A continually updated summary of the evidence for sucralose and low- and no-calorie sweeteners.
Covers carcinogenicity, glycemic effects, the microbiome, insulin sensitivity, regulatory status, and established ADIs, with full citations.
Prefer to read by topic? Each of the clinical questions is available as its own referenced page with a downloadable one-pager.
Regulators set intake limits with a large safety buffer, well above what people consume.
Highest experimental dose free from any adverse effect.
Scales with body weight.7
NOAEL divided by a 100‑fold safety factor.
Sucralose ADI: 5‑15 mg/kg BW/day.1,2,3
Estimated real-world intake, a measured population average well below the ADI.4,9 Ten packets a day is on the high end of typical use.
The ADI is a conservative measurement: it is the NOAEL reduced by a large safety factor.
The NOAEL is the highest experimental dose that produces no adverse effect at all.7
Dividing the NOAEL by 100 yields the ADI, the amount safe to consume every day. For sucralose: 5-15 mg/kg BW/day.1,2,3
The EDI is estimated from actual consumption and compared to the ADI. For sucralose it sits well below the limit.4,6,9
Real-world consumption of sucralose and other low- and no-calorie sweeteners is well below established safety levels in the US and globally.4,6,9
Every source cited across this site, listed alphabetically.
For healthcare professionals only. Illustrative prototype; not for external use without medical, regulatory, and legal review.